Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lung Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
brigatinib × 90 days × Clear all
NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting
109 enrolled
CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT05100069 2026-03-17

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Takeda

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡